Short-term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort
Abstract Background For clinical implementation of Alzheimer’s disease (AD) blood-based biomarkers (BBMs), knowledge of short-term variability, is crucial to ensure safe and correct biomarker interpretation, i.e., to capture changes or treatment effects that lie beyond that of expected short-term va...
Saved in:
Main Authors: | Frederikke Kragh Clemmensen, Mathias Holsey Gramkow, Anja Hviid Simonsen, Nicholas J. Ashton, Hanna Huber, Kaj Blennow, Henrik Zetterberg, Gunhild Waldemar, Steen Gregers Hasselbalch, Kristian Steen Frederiksen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-024-01658-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unveiling neurogenic biomarkers for the differentiation between sepsis patients with or without encephalopathy: an updated meta-analysis
by: Jiyun Hu, et al.
Published: (2025-02-01) -
Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease
by: Tapas K. Sur, et al.
Published: (2025-06-01) -
C/EBPβ in Alzheimer’s disease: An integrative regulator of pathological mechanisms
by: Xiaoting Luo, et al.
Published: (2025-02-01) -
Natural bioactive compounds form herbal medicine in Alzheimer’s disease: from the perspective of GSK-3β
by: Mei Wang, et al.
Published: (2025-02-01) -
Peripheral proteinopathy in neurodegenerative diseases
by: Bin Xu, et al.
Published: (2025-01-01)